P045 | FIRST-LINE NIVOLUMAB-AVD FOR ADVANCED CLASSICAL HODGKIN LYMPHOMA IN ELDERLY PATIENTS: A SINGLE-CENTRE EXPERIENCE
Background The phase-III SWOG S1826 study established nivolumab-AVD (N-AVD) as a less-toxic, first-line option for advanced classical Hodgkin lymphoma (cHL), including patients ≥ 60 years. On the basis of those data, our centre introduced an attenuated-dose N-AVD programme for elderly or comorbid pa...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Ferrata Storti Foundation
2025-09-01
|
| Col·lecció: | Haematologica |
| Accés en línia: | https://haematologica.org/article/view/12542 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|